Bionano Reports Preliminary Fourth Quarter and Full-Year 2025 Results

Core Insights - Bionano Genomics reported preliminary financial results for Q4 and the full year 2025, highlighting a strategic transformation towards routine users of optical genome mapping (OGM) solutions and improved financial metrics [2][3]. Financial Performance - Total revenue for Q4 2025 is projected to be between $7.8 million and $8.0 million, reflecting a year-over-year decrease of 2% to 4% [6]. - For the full year 2025, total revenue is expected to be in the range of $28.4 million to $28.6 million, indicating a decrease of 7% to 8% year-over-year [6]. - As of December 31, 2025, the company had approximately $29.6 million in cash and cash equivalents, with $10.3 million subject to restrictions [3]. Business Developments - The company established a second category I CPT code for OGM in constitutional genetic disorders and saw a 47% increase in payment determination for the existing CPT code related to hematologic malignancies [2]. - Bionano experienced significant growth in published clinical research supporting OGM as an alternative to traditional cytogenetic methods, with an increase in peer-reviewed publications and reported clinical research genomes [2]. - The company installed 9 new OGM systems in Q4 2025, contributing to a total of 387 installed systems by year-end, up from 371 at the end of 2024 [6].